A first-in-class, non-invasive, immunodynamic biomarker approach for precision immuno-oncology

Non-invasive, immuno-dynamic, biomarkers positioned in cancer patient’s blood milieu with immuno-oncological applications are rare. We recently established a “first-in-class” serum functional immunodynamics status (sFIS) assay, wherein in vitro assessment of serum-induced myeloid NFkB and/or interfe...

Descripción completa

Detalles Bibliográficos
Autores principales: Sprooten, Jenny, Coosemans, An, Garg, Abhishek D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8757472/
https://www.ncbi.nlm.nih.gov/pubmed/35036075
http://dx.doi.org/10.1080/2162402X.2021.2024692
_version_ 1784632688660971520
author Sprooten, Jenny
Coosemans, An
Garg, Abhishek D.
author_facet Sprooten, Jenny
Coosemans, An
Garg, Abhishek D.
author_sort Sprooten, Jenny
collection PubMed
description Non-invasive, immuno-dynamic, biomarkers positioned in cancer patient’s blood milieu with immuno-oncological applications are rare. We recently established a “first-in-class” serum functional immunodynamics status (sFIS) assay, wherein in vitro assessment of serum-induced myeloid NFkB and/or interferon (IFN) response-signaling can be performed to “mimic” in situ patient’s serum immune-biology. This modality has clear implications for anticipating patient prognosis and immunotherapy-relevant stratification.
format Online
Article
Text
id pubmed-8757472
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-87574722022-01-14 A first-in-class, non-invasive, immunodynamic biomarker approach for precision immuno-oncology Sprooten, Jenny Coosemans, An Garg, Abhishek D. Oncoimmunology Research Article Non-invasive, immuno-dynamic, biomarkers positioned in cancer patient’s blood milieu with immuno-oncological applications are rare. We recently established a “first-in-class” serum functional immunodynamics status (sFIS) assay, wherein in vitro assessment of serum-induced myeloid NFkB and/or interferon (IFN) response-signaling can be performed to “mimic” in situ patient’s serum immune-biology. This modality has clear implications for anticipating patient prognosis and immunotherapy-relevant stratification. Taylor & Francis 2022-01-10 /pmc/articles/PMC8757472/ /pubmed/35036075 http://dx.doi.org/10.1080/2162402X.2021.2024692 Text en © 2022 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Sprooten, Jenny
Coosemans, An
Garg, Abhishek D.
A first-in-class, non-invasive, immunodynamic biomarker approach for precision immuno-oncology
title A first-in-class, non-invasive, immunodynamic biomarker approach for precision immuno-oncology
title_full A first-in-class, non-invasive, immunodynamic biomarker approach for precision immuno-oncology
title_fullStr A first-in-class, non-invasive, immunodynamic biomarker approach for precision immuno-oncology
title_full_unstemmed A first-in-class, non-invasive, immunodynamic biomarker approach for precision immuno-oncology
title_short A first-in-class, non-invasive, immunodynamic biomarker approach for precision immuno-oncology
title_sort first-in-class, non-invasive, immunodynamic biomarker approach for precision immuno-oncology
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8757472/
https://www.ncbi.nlm.nih.gov/pubmed/35036075
http://dx.doi.org/10.1080/2162402X.2021.2024692
work_keys_str_mv AT sprootenjenny afirstinclassnoninvasiveimmunodynamicbiomarkerapproachforprecisionimmunooncology
AT coosemansan afirstinclassnoninvasiveimmunodynamicbiomarkerapproachforprecisionimmunooncology
AT gargabhishekd afirstinclassnoninvasiveimmunodynamicbiomarkerapproachforprecisionimmunooncology
AT sprootenjenny firstinclassnoninvasiveimmunodynamicbiomarkerapproachforprecisionimmunooncology
AT coosemansan firstinclassnoninvasiveimmunodynamicbiomarkerapproachforprecisionimmunooncology
AT gargabhishekd firstinclassnoninvasiveimmunodynamicbiomarkerapproachforprecisionimmunooncology

Ejemplares similares